Article Sidebar

PDF
Date Published: 21/04/2022
Abstract Views: 2538
Views PDF: 397
DOI: https://doi.org/10.51298/vmj.v511i2.2170
Issue
Vol. 511 No. 2 (2022)
Section
Các bài báo
How to Cite
Thị Thanh Nhàn, D. ., Thanh Phượng, H. ., & Thị Tuyết Hạnh, N. (2022). A STUDY OF TTF1 AND p63 EXPRESSION IN PRIMARY NON-SMALL CELL LUNG CARCINOMA. Vietnam Medical Journal, 511(2). https://doi.org/10.51298/vmj.v511i2.2170

A STUDY OF TTF1 AND p63 EXPRESSION IN PRIMARY NON-SMALL CELL LUNG CARCINOMA

Dương Thị Thanh Nhàn1,, Huỳnh Thanh Phượng2, Ngô Thị Tuyết Hạnh2
1 Can Tho Oncology Hospital
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Background: Chemotherapies or targeted therapies are difference that depend on hostopathological subtype of non-small cell lung cancer group. TTF1 and p63 play an important role in subclassifying non-small cell lung carcinoma. Objectives: The research aims to classify morphology of non-small cell lung carcinoma according to the WHO classification of lung cancer 5th edition and evaluate the rate of TTF1 and p63 expression in non-small cell lung carcinoma. Methods: A retrospective, case series report of primary lung cancer from January-2017 to June-2020 at Ho Chi Minh University of Medicine and Pharmacy Hospital met the critiria of non-small cell lung carcinoma according to post-operative pathologic findings. Immunohistochemistry staining for TTF1 and p63 were carried out for all these cases and the expression was recorded in comparison with normal cells. Results: Out of total 83 cases, 72,3% cases were possitive 3+, 19,8% cases were possitive 2+ and 16,8% cases were negative for TTF1. p63 expression was 4,8% cases possitive 3+, 10,8% cases possitive 2+, 10,8% cases possitive 1+ and 73,5% cases negative for p63. Conclusions: TTF1 and p63 are reliable immunohistochemistry markers for classifying non-small cell lung carcinoma. It is also important to use the WHO classification of lung cancer 5th edition.

Article Details

Keywords

TTF1 and p63, non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, WHO Classification of Lung cancer

References

1. Phạm Nguyên Cường (2014), Nghiên cứu phân loại mô bệnh học Ung thư biểu mô phổi theo WHO 2004 và IASLC/ATS/ERS 2011 có sử dụng dấu ấn hóa mô miễn dịch, Luận văn Thạc sĩ Y khoa, Đại học Y Hà Nội.
2. Nguyễn Văn Tình (2011), Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và ứng dụng phân loại mô bệnh học ung thư biểu mô tuyến phế quản theo Hiệp hội ung thư phổi quốc tế năm 2011, Luận văn Thạc sĩ Y khoa, Đại học Y Hà Nội.
3. Asuman A., et al. (2015), “The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung”, Turk Patoloji Derg, 31, pp.81-88
4. Banu Y, et al. (2015), “Expression of p63, TTF–1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis”, Turk Patoloji Derg, 31, pp. 163-174.
5. Jing-yuan W, et al. (2020), “Expression and Significance of CK5/6, P63, P40, CK7, TTF-1, NapsinA, CD56, Syn and CgA in Biopsy Specimen of Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Lung Carcinoma”, Int. J. Morphol, 38(2), pp. 247-251.
6. Siegal RL, Miller KD (2016), “Cancer statistics”, Cancer J Clin, 66(1), pp. 7-30.
7. Travis WD, et al. (2015), WHO Classification of Tumor of the Lung, Pleura, Thymus and Heart, 4th edition, IARC/WHO, France, pp. 9-148.
8. Travis WD, et al (2021), The 2021 WHO Thoracic Tumor, 5th edition, IARC/WHO, France, pp. 19-193.
9. Warth A, Muley T, Herpel E, et al. (2012), “Largescale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies”, Histopathology, 61(6), pp. 1017-1025.